LBO — GEISINGER WYOMING VALLEY MED CTR
IRR: 20.7% | MOIC: 2.56x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
20.7%
IRR
2.56x
MOIC
$479.7M
Entry EV
$844.9M
Exit EV
$246.8M
Equity Invested
Sources & Uses
S&UTotal · $479.7M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $186.3M | 38.8% | |
| Sub Debt | $46.6M | 9.7% | |
| Equity | $246.8M | 51.5% | |
| Enterprise Value | $465.7M | 97.1% | |
| Transaction Fees | $14.0M | 2.9% | |
| Total Uses | $479.7M | 100.0% |
Interpretation
INTAt 2.56x MOIC and 20.7% IRR over 5 years, this deal exceeds the typical 20% hurdle — strong candidate.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $80.5M |
| Exit Ev | $844.9M |
| Net Debt At Exit | $213.4M |
| Equity At Exit | $631.5M |
| Equity Invested | $246.8M |
| Total Value Created | $384.7M |
| Value From Growth | $355.9M |
| Value From Multiple | $23.3M |
| Value From Deleveraging | $19.4M |